# UTHR catalysts: UNITED THERAPEUTICS Corp PDUFA dates and FDA events

Canonical: https://sec-api.dev/companies/uthr/catalysts

> UNITED THERAPEUTICS Corp (UTHR) has 11 upcoming catalysts. The next is the ralinepag primary completion, December 2026.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, month only, half-year only, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Company

| Field | Value |
| --- | --- |
| Name | UNITED THERAPEUTICS Corp |
| Ticker | UTHR (Nasdaq) |
| SEC CIK | 1082554 |
| SIC | 2834 |
| SEC filings | https://sec-api.dev/companies/uthr |

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| October 7, 2016 | [YUTREPIA (treprostinil) complete response letter (CRL)](https://sec-api.dev/pdufa/treprostinil) | UTHR |  | completed, complete response letter | "We have completed our review of this application, as amended, and have determined that we cannot approve this application in its present form." ([FDA complete response letter database](https://api.fda.gov/transparency/crl.json?search=file_name:%22208276_2018_Orig1s000OtherActionLtrs.pdf%22)) |
| June 2, 2017 | [YUTREPIA (treprostinil) complete response letter (CRL)](https://sec-api.dev/pdufa/treprostinil) | UTHR |  | completed, complete response letter | "We have completed our review of this application, as amended, and have determined that we cannot approve this application in its present form." ([FDA complete response letter database](https://api.fda.gov/transparency/crl.json?search=file_name:%22208276_2018_Orig1s000OtherActionLtrs.pdf%22)) |
| October 15, 2021 | [YUTREPIA (treprostinil) complete response letter (CRL)](https://sec-api.dev/pdufa/treprostinil) | UTHR |  | completed, complete response letter | "We have completed our review of this application, as amended, and have determined that we cannot approve this application in its present form." ([FDA complete response letter database](https://api.fda.gov/transparency/crl.json?search=file_name:%22214324_2022_Orig1s000OtherActionLtrs.pdf%22)) |
| February 26, 2025 | [UNITED THERAPEUTICS Corp earnings report](https://sec-api.dev/companies/uthr/catalysts) | UTHR |  | completed | "United Therapeutics Corporation Reports Fourth Quarter and Full Year 2024 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1082554/000108255425000007/exhibit991uthr12312024.htm)) |
| April 30, 2025 | [UNITED THERAPEUTICS Corp earnings report](https://sec-api.dev/companies/uthr/catalysts) | UTHR |  | completed | "United Therapeutics Corporation Reports First Quarter 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1082554/000108255425000024/uthrq12025-ex991.htm)) |
| June 30, 2025 | [Inhaled treprostinil primary completion](https://sec-api.dev/pdufa/inhaled-treprostinil) | UTHR | Idiopathic Pulmonary Fibrosis; Interstitial Lung Disease | completed | "NCT05255991 (Multinational Study of Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-06-30 (ACTUAL); Lead Sponsor United Therapeutics; Results First Posted 2026-10-15." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05255991)) |
| July 30, 2025 | [UNITED THERAPEUTICS Corp earnings report](https://sec-api.dev/companies/uthr/catalysts) | UTHR |  | completed | "United Therapeutics Corporation Reports Record Second Quarter 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1082554/000162828025036543/uthrq22025-ex991.htm)) |
| Sep 2025 | [UNITED THERAPEUTICS Corp topline data readout](https://sec-api.dev/companies/uthr/catalysts) | UTHR |  | scheduled | "We anticipate announcing topline data from the TETON 2 study in September 2025, and from the TETON 1 study during the first half of 2026." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1082554/000162828025036541/uthr-20250630.htm)) |
| October 29, 2025 | [UNITED THERAPEUTICS Corp earnings report](https://sec-api.dev/companies/uthr/catalysts) | UTHR |  | completed | "United Therapeutics Corporation Reports Record Third Quarter 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1082554/000108255425000036/uthrq32025-ex991.htm)) |
| December 31, 2025 | [Ralinepag primary completion](https://sec-api.dev/pdufa/ralinepag) | UTHR | PAH; Pulmonary Hypertension; Pulmonary Arterial Hypertension | completed | "NCT03626688 (A Study Evaluating the Efficacy and Safety of Ralinepag to Improve Treatment Outcomes in PAH Patients): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-12-31 (ACTUAL); Lead Sponsor United Therapeutics." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT03626688)) |
| 1H 2026 | [UNITED THERAPEUTICS Corp topline data readout](https://sec-api.dev/companies/uthr/catalysts) | UTHR |  | scheduled | "We expect to continue accruing clinical worsening events in this study through the end of 2025, and release topline data from the study in the first half of 2026." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1082554/000108255425000034/uthr-20250930.htm)) |
| February 2, 2026 | [Inhaled treprostinil primary completion](https://sec-api.dev/pdufa/inhaled-treprostinil) | UTHR | Idiopathic Pulmonary Fibrosis; Interstitial Lung Disease | completed | "NCT04708782 (Study of Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-02-02 (ACTUAL); Lead Sponsor United Therapeutics." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04708782)) |
| February 25, 2026 | [UNITED THERAPEUTICS Corp earnings report](https://sec-api.dev/companies/uthr/catalysts) | UTHR |  | completed | "United Therapeutics Corporation Reports Fourth Quarter and Full Year 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1082554/000108255426000007/exhibit991uthr12312025.htm)) |
| May 6, 2026 | [UNITED THERAPEUTICS Corp earnings report](https://sec-api.dev/companies/uthr/catalysts) | UTHR |  | completed | "United Therapeutics Corporation Reports First Quarter 2026 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1082554/000108255426000021/uthrq12026-ex991.htm)) |
| Jun 2026 | [Tyvaso (tyvaso) NDA/BLA submission](https://sec-api.dev/pdufa/tyvaso) | UTHR |  | completed | "In June 2026, we submitted a supplemental NDA (sNDA) to the FDA to add IPF to the labeled indications for Nebulized Tyvaso." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1082554/000108255426000035/uthr-20260930.htm)) |
| Jun 2026 | [Ralinepag NDA/BLA submission](https://sec-api.dev/pdufa/ralinepag) | UTHR |  | completed | "In June 2026, we submitted an NDA to the FDA seeking approval to market ralinepag extended-release tablets for PAH." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1082554/000108255426000035/uthr-20260930.htm)) |
| Aug 2026 | [Ralinepag NDA/BLA acceptance](https://sec-api.dev/pdufa/ralinepag) | UTHR |  | completed | "In August 2026, we were notified that the FDA had accepted our NDA and established a user fee goal date of June 24, 2027." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1082554/000108255426000035/uthr-20260930.htm)) |
| August 5, 2026 | [UNITED THERAPEUTICS Corp earnings report](https://sec-api.dev/companies/uthr/catalysts) | UTHR |  | completed | "United Therapeutics Corporation Reports Second Quarter 2026 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1082554/000108255426000028/uthrq22026-ex991.htm)) |
| Sep 2026 | [Ofev® (nintedanib) NDA/BLA acceptance](https://sec-api.dev/pdufa/nintedanib) | UTHR |  | completed | "In September 2026, we were notified that the FDA had accepted our sNDA with a user fee goal date of April 26, 2027." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1082554/000108255426000035/uthr-20260930.htm)) |
| October 15, 2026 | [Inhaled treprostinil topline data readout](https://sec-api.dev/pdufa/inhaled-treprostinil) | UTHR | Idiopathic Pulmonary Fibrosis; Interstitial Lung Disease | completed | "NCT05255991 (Multinational Study of Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-06-30 (ACTUAL); Lead Sponsor United Therapeutics; Results First Posted 2026-10-15." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05255991?tab=results)) |
| November 4, 2026 | [UNITED THERAPEUTICS Corp earnings report](https://sec-api.dev/companies/uthr/catalysts) | UTHR |  | completed | "United Therapeutics Corporation Reports Third Quarter 2026 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1082554/000108255426000036/uthrq32026-ex991.htm)) |
| December 2026 | [Ralinepag primary completion](https://sec-api.dev/pdufa/ralinepag) | UTHR | PAH; Pulmonary Hypertension; Pulmonary Arterial Hypertension | scheduled | "NCT03683186 (A Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension): Overall Status ENROLLING_BY_INVITATION; Phase PHASE3; Primary Completion 2026-12 (ESTIMATED); Lead Sponsor United Therapeutics." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT03683186)) |
| Dec 2026 to Mar 2027 | [Ralinepag topline data readout](https://sec-api.dev/pdufa/ralinepag) | UTHR | PAH; Pulmonary Hypertension; Pulmonary Arterial Hypertension | scheduled | "NCT03683186 (A Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension): Overall Status ENROLLING_BY_INVITATION; Phase PHASE3; Primary Completion 2026-12 (ESTIMATED); Lead Sponsor United Therapeutics." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT03683186)) |
| April 26, 2027 | [Ofev® (nintedanib) PDUFA date](https://sec-api.dev/pdufa/nintedanib) | UTHR |  | scheduled | "In September 2026, we were notified that the FDA had accepted our sNDA with a user fee goal date of April 26, 2027." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1082554/000108255426000035/uthr-20260930.htm)) |
| June 24, 2027 | [Ralinepag PDUFA date](https://sec-api.dev/pdufa/ralinepag) | UTHR |  | scheduled | "In August 2026, we were notified that the FDA had accepted our NDA and established a user fee goal date of June 24, 2027." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1082554/000108255426000035/uthr-20260930.htm)) |
| 2H 2027 | [UNITED THERAPEUTICS Corp topline data readout](https://sec-api.dev/companies/uthr/catalysts) | UTHR |  | scheduled | "We expect topline data from the TETON-PPF study will be available in the second half of 2027." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1082554/000108255426000035/uthr-20260930.htm)) |
| November 2027 | [Inhaled treprostinil primary completion](https://sec-api.dev/pdufa/inhaled-treprostinil) | UTHR | Progressive Pulmonary Fibrosis; Interstitial Lung Disease | scheduled | "NCT05943535 (Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-11 (ESTIMATED); Lead Sponsor United Therapeutics." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05943535)) |
| Nov 2027 to Feb 2028 | [Inhaled treprostinil topline data readout](https://sec-api.dev/pdufa/inhaled-treprostinil) | UTHR | Progressive Pulmonary Fibrosis; Interstitial Lung Disease | scheduled | "NCT05943535 (Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-11 (ESTIMATED); Lead Sponsor United Therapeutics." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05943535)) |
| May 2028 | [Treprostinil smi (treprostinil inhalation spray) primary completion](https://sec-api.dev/pdufa/treprostinil-smi-treprostinil-inhalation-spray) | UTHR | Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease | scheduled | "NCT07923591 (Study of Treprostinil Administered Via Soft Mist Inhaler (SMI) in Participants With Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease (PH-COPD)): Overall Status NOT_YET_RECRUITING; Phase PHASE2; Primary Completion 2028-05 (ESTIMATED); Lead Sponsor United Therapeutics." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07923591)) |
| May to Aug 2028 | [Treprostinil smi (treprostinil inhalation spray) topline data readout](https://sec-api.dev/pdufa/treprostinil-smi-treprostinil-inhalation-spray) | UTHR | Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease | scheduled | "NCT07923591 (Study of Treprostinil Administered Via Soft Mist Inhaler (SMI) in Participants With Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease (PH-COPD)): Overall Status NOT_YET_RECRUITING; Phase PHASE2; Primary Completion 2028-05 (ESTIMATED); Lead Sponsor United Therapeutics." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07923591)) |
| December 2029 | [Inhaled treprostinil primary completion](https://sec-api.dev/pdufa/inhaled-treprostinil) | UTHR | Idiopathic Pulmonary Fibrosis; Interstitial Lung Disease; Progressive Pulmonary Fibrosis | scheduled | "NCT04905693 (Extension Study of Inhaled Treprostinil in Subjects With Fibrotic Lung Disease): Overall Status ENROLLING_BY_INVITATION; Phase PHASE3; Primary Completion 2029-12 (ESTIMATED); Lead Sponsor United Therapeutics." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04905693)) |
| Dec 2029 to Mar 2030 | [Inhaled treprostinil topline data readout](https://sec-api.dev/pdufa/inhaled-treprostinil) | UTHR | Idiopathic Pulmonary Fibrosis; Interstitial Lung Disease; Progressive Pulmonary Fibrosis | scheduled | "NCT04905693 (Extension Study of Inhaled Treprostinil in Subjects With Fibrotic Lung Disease): Overall Status ENROLLING_BY_INVITATION; Phase PHASE3; Primary Completion 2029-12 (ESTIMATED); Lead Sponsor United Therapeutics." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04905693)) |

## Drugs

- [Inhaled treprostinil](https://sec-api.dev/pdufa/inhaled-treprostinil): Idiopathic Pulmonary Fibrosis, Progressive Pulmonary Fibrosis
- [Ralinepag](https://sec-api.dev/pdufa/ralinepag): PAH
- [YUTREPIA (treprostinil)](https://sec-api.dev/pdufa/treprostinil): pah and ph-ild in may 2025, pah and ph-ild, pulmonary arterial hypertension, rare cardiopulmonary disease, rare cardiopulmonary disease, today
- [Treprostinil smi (treprostinil inhalation spray)](https://sec-api.dev/pdufa/treprostinil-smi-treprostinil-inhalation-spray): Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease
- [Tyvaso (tyvaso)](https://sec-api.dev/pdufa/tyvaso): 

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/companies/uthr/catalysts.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "UTHR catalysts: UNITED THERAPEUTICS Corp PDUFA dates and FDA events." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/companies/uthr/catalysts

```bibtex
@misc{secapidev_companies_uthr_catalysts_20261116,
  title        = {UTHR catalysts: UNITED THERAPEUTICS Corp PDUFA dates and FDA events},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/companies/uthr/catalysts}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_companies_uthr_catalysts_20261116","title":"UTHR catalysts: UNITED THERAPEUTICS Corp PDUFA dates and FDA events","publisher":"sec-api.dev","URL":"https://sec-api.dev/companies/uthr/catalysts","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
